A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

NCT07160335 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

174

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
Melanoma
Renal Cell Carcinoma

Interventions

DRUG: HLX17
DRUG: US-sourced Keytruda®

Sponsor

Shanghai Henlius Biotech